The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer

Chen Fan†, Yijie Wang†, Hui Huang†, Wenzhen Li‡, Jialin Ma‡, Dongping Yao‡, Zijun Tang‡, Taixiong Xue‡, Liyang Ha†, Yan Ren†, Yiwang Zhang‡, Qin Wang‡, Yongmei Xie‡, Yi Luo‡*, Rui Tan§* and Jian Gu¶*

1College of Pharmacy, Southwest Minzu University, Chengdu, China, 2State Key Laboratory of Biotherapy and Cancer Center, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China, 3Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, China, 4College of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China

Breast cancer is the most common malignancy in women and is a molecularly heterogeneous disease. Signal transducer and activator of transcription 3 (Stat3) is overexpressed and hyperactivated in a variety of human tumours, including breast cancer, thus representing a promising target for breast cancer treatment. In the present study, we evaluated the activities of a novel Stat3 inhibitor named Statmp-151 in the human breast cancer cell lines MCF-7 and MDA-MB-231 and the murine mammary carcinoma cell line 4T1. The in vitro results showed that Statmp-151 inhibited the proliferation of breast cancer cell lines in a dose- and time-dependent manner and suppressed the phosphorylation of Stat3 in a dose-dependent manner. Flow cytometry (FCM) assays revealed that Statmp-151 affected mitochondrial membrane potential and reactive oxygen species (ROS) production. Furthermore, Statmp-151 inhibited cell migration, as shown by analysis of the matrix metalloproteinases MMP2 and MMP9. Finally, in a 4T1 tumour-bearing mouse model, intraperitoneal injection of 30 mg/kg/day Statmp-151 significantly suppressed the growth of tumours without obvious toxicity. These results indicated that Statmp-151 might be a potential candidate for the treatment of breast cancer.

Keywords: breast cancer, tetramethylpyrazine derivatives, stat3, statmp-151, apoptosis

INTRODUCTION

Breast cancer is a major cause of cancer-related mortality as one of the most common cancers in females. The strong metastatic potential of this disease accounts for most deaths from breast cancer. Treatment for breast cancer is multidisciplinary, including locoregional surgery and radiotherapy as well as systemic treatment (Harbeck et al., 2019). Triple-negative breast cancer (TNBC) is the most aggressive type and has much higher recurrence and metastasis rates than other types (Waks and Winer, 2019). When patients are diagnosed with TNBC at the early stage, a combination of chemotherapeutic agents with radiotherapy or no radiotherapy is used as the standard nonsurgical treatment; unfortunately, the efficacy is limited (Sharma and Priyanka, 2018). In addition to chemotherapy and surgery, molecular-targeted therapy has been one of the hotspots in the field of breast cancer research in recent years (Lu and Liu, 2020).
Stat3 regulates tyrosinase gene expression and transcript activity and thus plays a pivotal role in promoting breast cancer growth and metastasis (Federica et al., 2018). The Stat3 protein consists of an N-terminal domain, a coiled-coil domain (CCD), a DNA binding domain (DBD), a linker domain, an SRC homology 2 (SH2) domain for phosphorylation and dimerization, and a C-terminal transactivation domain (TAD) (Furtek et al., 2016). The SH2 domain is a very important domain of Stat3 and is related to many important physiological functions of Stat3. When extracellular signals are transmitted to the cell membrane, through a series of cascade amplification reactions, tyrosine 705 (Tyr705) of the SH2 domain is finally phosphorylated to activate the entire Stat3. The activated Stat3 monomer dimerizes through the SH2 domain and enters the nucleus, binding with DNA and promoting the expression of downstream genes (Schust et al., 2006; Chen et al., 2013).

Therefore, targeted inhibitors of the SH2 domain may have potential to treat breast cancer. However, targeted inhibitors of the SH2 domain possess many disadvantages, such as high toxicity, low activity and poor selectivity. Tetramethylpyrazine (TMP) is an alkaloid isolated from the rhizome of *Ligusticum chuanxiong* Hort. TMP has been reported to have several significant biological effects, such as antioxidative, antiobrotic, calcium antagonist and antitumour effects (Zhao et al., 2016). TMP could also inhibit the viability of MDA-MB-231 breast cancer cells (Shen et al., 2018). However, the anticancer activity is relatively weak. Hence, it is necessary to enhance its effects via reasonable structural modification. In this study, we synthesized Statmp-151 to improve TMP’s anti-breast cancer activity; this molecule combined the classic SH2 domain targeting inhibitor Stat with TMP (Zeng et al., 2013; Furtek et al., 2016). Finally, the potential anti-breast cancer mechanisms were explored by a series of experiments.

**MATERIALS AND METHODS**

**Cell Culture**
The breast cancer cell lines MCF-7, MDA-MB-231 and 4T1 were purchased from the American Type Culture Collection (Rockville, MD, United States). Cells were maintained in DMEM or RPMI 1640 medium supplemented with 10% foetal bovine serum (Si Ji Qin Bioengineering, China) and 1% antibiotics (penicillin and streptomycin) at 37°C in a 5% CO$_2$ incubator.

**Cell Viability and Colony Formation Assays**
The cells (1 × 10$^5$ cells per well) were incubated in 96-well plates overnight and then treated with different concentrations of Statmp-151 for 24, 48, and 72 h. Afterward, 5 mg/ml MTT (20 µl) was added to each well for 3 h. Finally, the supernatant was removed, and 150 µl of DMSO was added to each well. The optical density values were determined at 490 or 570 nm by a SpectraMAX M5 Microplate Spectrophotometer. All experiments were performed three times with three replicates.

Colony formation was measured by seeding cells in 6-well plates at 500–800 cells per well and treating the cells with various concentrations of Statmp-151 after approximately 24 h of incubation. The culture medium containing Statmp-151 was replaced every three days. All cells were fixed and stained with 0.5% crystal violet after 12 days.

**Apoptosis Analysis**
For determination of the effect of Statmp-151 on tumour apoptosis, apoptosis detection kits were used. The cells (1 × 10$^5$ cells per well) were incubated in 6-well plates overnight and then treated with different concentrations of Statmp-151. After 24 h, the cells were harvested and washed twice with cold PBS. Following the manufacturer’s instructions, the cells were stained with FITC-conjugated Annexin V and PI (Propidium Iodide) and detected by FCM.

**Mitochondrial Membrane Potential (Δψm)**
The cells (1 × 10$^5$ cells per well) were incubated in 6-well plates overnight, and treated with Statmp-151 for another 24 h. Then, the cells were harvested and washed twice with cold PBS, stained with JC-1 according to the instructions, and finally detected by FCM.

**Reactive Oxygen Species Level in Cells**
The cells (1 × 10$^5$ cells per well) were incubated in 6-well plates overnight and then treated with different concentrations of Statmp-151. After 24 h, the cells were harvested and washed twice with cold PBS. The ROS levels were monitored using 10 µM DCFH-DA for 30 min and then detected by FCM.

**Western Blotting**
For analysis of the expression of the corresponding proteins in MDA-MB-231 and 4T1 cells after incubation with Statmp-151 for 24 h, harvested cells were lysed with RIPA buffer for 1 h. Then, the protein concentrations were measured and equalized. SDS-PAGE with the optimal concentration of proteins selected according to their molecular weight was performed, and then, the proteins were transferred onto polyvinylidene difluoride nitrocellulose membranes. After incubation with 5% skim milk for 1 h, the target protein was incubated with the corresponding primary antibodies overnight at 4°C. The next day, the cells were washed several times and then incubated with the corresponding secondary antibodies, followed by washing several times. Finally, the protein bands were visualized using an enhanced chemiluminescence kit. Monoclonal β-actin proteins were used as a reference.

**Wound-Healing Migration Assays**
A wound-healing migration assay was performed to evaluate cell migration. When cells grew to 80% confluence in 6-well plates, they were renewed with 2% FBS containing different concentrations of Statmp-151. Images were taken at 0 and 24 h by an inverted microscope.

**The Anticancer Effect of Statmp-151 In Vivo**
All animal experiments were conducted in accordance with the principles and procedures approved by the Committee on the Ethics of Animal Experiments of State Key Laboratory of Biotherapy, Sichuan University. BALB/c mice aged 6–8 weeks...
were purchased from the experimental Animal Centre of Sichuan University. Approximately $1 \times 10^6$ 4T1 cells were inoculated into the right lower limb of the mice. We randomly divided the mice into 4 groups ($n = 5$) when the tumours reached an average volume of 100 mm$^3$. Statmp-151 (10, 20, and 30 mg/kg) or vehicle was intraperitoneally injected once a day for 15 days. After administration, the body weights and tumour sizes of the mice were measured every 3 days. At the end of the animal experiment, the weight of the tissue and tumour was recorded, and then, the tumour volume was measured and photographed. The tumour tissue was stored in paraformaldehyde for further analysis.

**Toxicity Evaluation**

For evaluation of the safety of Statmp-151 during the treatment, all the mice were observed continuously for general conditions, such as body weight, appetite, mental state and other clinical features. Blood was obtained from the eyeball for biochemistry analysis. Haematoxylin and eosin staining was performed of paraffin sections of lung, liver, spleen, heart and kidney tissues of the mice treated with Statmp-151.

**Statistical Analysis**

The results are presented as the mean and standard deviation (M±SD). Statistically significant $p$ values were labelled as follows: *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$. All statistical workflows were performed in GraphPad Prism (version 7.0).

**RESULTS**

**Drug Design of Statmp-151**

TMP was reported to possess multiple activities, as described above. For chemical structure modification, there are three common fragments of TMP to utilize (Figure 1A). Carboxyl, bromo and hydroxyl groups are operable reactive groups for
various modification strategies. Stat3-targeted inhibitors, such as Stattic, BBI608, LLL12, HJC0146, LY-5 and STA-21, are listed in Figure 1B. Among them, Stattic was the first small molecule inhibitor of Stat3 activation and dimerization (Schust et al., 2006). This compound is often used for further development to discover Stat3 inhibitors (Ji et al., 2015). In this study, we used (5-bromo-1,1-dioxidobenzo[b]thiophen-2-yl) (piperidin-1-yl) methanone (E28) (Ji et al., 2015) as the lead compound to discover Stat3 inhibitors containing TMP. We replaced the piperazine ring of E28 with a piperazine ring for further modification (in blue circle) and explored the group linking TMP with the piperazine ring. In terms of the scaffold of Stattic, we also explored the substituents on the benzene ring (in red circle), and a total of 38 compounds were designed (Figure 1C). We employed the Glide docking program to conduct a virtual screening against these 38 rationally designed Statmp series and finally found that Statmp-151 could exhibit potent activity against Stat3, had the best docking score and showed a more favourable conformation (Figure 2). Binding mode analysis indicated that the pyrazine ring and sulfone form hydrogen bonds with Lys591, while the bromo substituent forms halogen bonds with Arg595. Then, wet laboratory experiments were conducted to explore whether Statmp-151 was consistent with the primary drug design. The synthesis and characterization of Statmp-151 are shown in the supporting information.

Statmp-151 Inhibited the Growth of Breast Cancer Cells In Vitro

The effects of Statmp-151 on the proliferation of MCF-7, MDA-MB-231 and 4T1 cells were detected by MTT assays (Liu et al., 2019). In 4T1 and MDA-MB-231 cells where Statmp-151 was used at concentrations of 0–20 µM, and in MCF-7 cells where Statmp-151 was used at concentrations of 0–40 µM for 24, 48 and 72 h. The results showed that the IC50 at 72 h was 2.20 ± 0.01 µM in 4T1 cells, 4.75 ± 0.39 µM in MDA-MB-231 cells, and 8.06 ± 0.08 µM in MCF-7 cells (Figure 3A). Pan J reported the anti-tumour activity of TMP which is not ideal. The ligustrazine IC50 results showed it is about 10 mmol/l in breast cancer. The above results significantly improved the anti-tumour activity of maternal TMP (Pan et al., 2015).
A clone formation experiment was utilized to further verify the effects of Statmp-151 on the proliferation of MDA-MB-231, MCF-7 and 4T1 cells. As shown in Figure 3B,C, cancer cell proliferation was reduced in a concentration-dependent manner, which was consistent with the results of the MTT assay.

**Statmp-151 Induced Apoptosis of Breast Cancer Cells**

For further analysis of the effect of Statmp-151, we performed Annexin V and PI double dye detection of MDA-MB-231 and 4T1 cells (Zhu et al., 2016). As shown in Figure 4A,B, Statmp-151 was able to induce breast cancer cell apoptosis in a dose-dependent manner after treatment for 24 h compared to that in the control group.

To confirm the apoptotic effect of Statmp-151 on breast cancer cells, we determined the expression of Bcl-2, Bax and Cleaved caspase-3 (CC3) in MDA-MB-231 and 4T1 cells after treatment with Statmp-151 for 24 h. As shown in Figure 4C,D, the expression level of Bcl-2 was strongly decreased in 4T1 cells, Bax expression was not changed, and CC3 expression was significantly increased. This treatment showed no effect on Bcl-2/Bax ratio expression and increased CC3 expression in MDA-MB-231 cells. Collectively, these results showed that Statmp-151 could induce breast cancer cell apoptosis.

**The Effect of Statmp-151 on Mitochondrial Membrane Potential and ROS**

Mitochondrial membrane potential is a marker of the early apoptotic pathway. During mitochondrial pathway-mediated
apoptosis, mitochondrial membrane permeability increases, stromal calcium outflow and mitochondrial membrane rupture occur, and apoptotic induction factor (AIF) and cytochrome C are released, thus initiating a cascade reaction to activate the caspase family and ultimately induce apoptosis (Reed, 1997). Mitochondrial membrane potential and intracellular ROS level jointly have a marker effect on the growth and development of cancer cells. When the mitochondrial membrane potential changes or the ROS level changes, it often indicates the loss of homeostasis of cancer cells. Once a compound has an inhibitory effect on cancer cells, these two indicators usually change (Zhao et al., 2016; Burke, 2017).

According to this knowledge, we detected the changes in mitochondrial membrane potential ($\Delta \Psi_m$) by FCM after treatment with different concentrations of Statmp-151 in breast cancer cells. As shown in Figure 5A,B, treatment with 10 µM Statpm-151 led to a 17.28% loss of $\Delta \Psi_m$ for 4T1 cells. The loss was 52.26% in MDA-MB-231 cells under the same conditions.

Tumor cells are often in an environment with a high level of reactive oxygen species (ROS), and intracellular ROS levels are closely related to the stability of the mitochondrial membrane potential (Li et al., 2011). The effect of Statmp-151 on membrane potential was identified in previous experiments, and the ligustrazine structure of Statmp-151 has been reported to reduce intracellular reactive oxygen species (Zhang et al., 2010). In view of this, we also determined the effect of Statmp-151 on ROS by FCM using DCFH-DA. The results indicated that Statmp-151 led to increased ROS levels in a dose-dependent manner. As shown in Figure 5C,D, the results showed that after 24 h of treatment with 10 µM Statmp-151...
in 4T1 and MDA-MB-231 cells, ROS levels were 18.89 and 48.72%, respectively. These results confirmed that Statmp-151 induced cell apoptosis via the mitochondrial-mediated apoptotic pathway.

Statmp-151 Inhibited Stat3 Phosphorylation
Phosphorylation by Jak kinase is a key step in the activation of Stat3 (Li et al., 2019); therefore, we detected whether Statmp-151 could influence the expression of p-Stat3. The results confirmed
that Statmp-151 could decrease the expression of p-Stat3 but had no effect on total Stat3 in MDA-MB-231 and 4T1 cells Figure 6. The results implied that Statmp-151 inhibited the phosphorylation of Stat3 proteins, consistent with the original drug design.

**Stamp-151 Inhibited the Migration of Breast Cancer Cells**

Tumour cell migration is one of the committed steps in cancer metastasis (Li et al., 2016). We conducted wound healing assays on 4T1 and MDA-MB-231 cells to explore the therapeutic potential of Statmp-151. As shown in Figure 7A,B, the results indicated that Statmp-151 significantly inhibited the migration of both 4T1 and MDA-MB-231 cells in a concentration-dependent manner. The migration of these cells to the wound area was significantly inhibited after incubation with Statmp-151 for 24 h at 10 µM.

To further verify the mechanism of the antimigratory effects of Statmp-151, we determined the MMP-9 and MMP-2 levels by western blotting. The results suggested that Statmp-151 could significantly inhibit the expression levels of MMP-2 and MMP-9 in 4T1 cells Figure 7C. These results suggested that Statmp-151 possessed a potent ability to inhibit breast cancer cell migration.

**In Vivo Anti-breast Cancer Activity of Statmp-151**

To evaluate the anti-tumour efficacy of Statmp-151 in vivo (Yang et al., 2015), we established a 4T1 tumour-bearing mouse model. The mice were administered Statmp-151 daily at doses of 10, 20 and 30 mg/kg for 15 days (Heppner et al., 2000; Zeng et al., 2020). There was a significant reduction in tumour growth, while the body weight of mice had no significant changes (Figure 8A,B). On the final day, there were significant reductions in tumor size and tumour weight compared with the control group (Figure 8C,D). These results suggested that Statmp-151 had potent anti-tumour activity in vivo.

As mentioned above, the body weights of the mice were not significantly changed. To further evaluate the safety of Statmp-151, we determined the serum biochemical indexes and weights of the heart, liver, spleen, lung and kidney. Paraffin sections of the lung, liver, spleen, heart and kidney were stained with haematoxylin and eosin. As shown in Figure 9A,B, there were no obvious differences in organ weight or serum biochemical indexes. Furthermore, no pathologic changes were observed in the lung, liver, spleen, heart or kidney compared with those in the control group Figure 9C. Therefore, Statmp-151 was considered to be a relatively safe small molecule compound.

**DISCUSSION**

Breast cancer is the most common malignancy in females and is a heterogeneous disease at the molecular level (Harbeck et al., 2019). Accumulating evidence has shown that Stat3 signalling is involved in breast cancer initiation and progression. Inhibition of the activity of Stat3 has become a popular therapeutic strategy (Zhang et al., 2010; Li et al., 2011; Alshaer et al., 2019; Xie et al., 2019). Therefore, the aim of this study was to explore the mechanisms of a novel small molecule inhibitor, Statmp-151,
in breast cancer cells and provide support for the treatment of breast cancer.

Stattic is one of the classic inhibitors of Stat3 but is limited by low activity, low selectivity and high toxicity (Zhang et al., 2010). Ligustrazine is an alkaloid found in nature whose structure is simple and easy to modify (Alshaer et al., 2019; Xie et al., 2019). Ligustrazine has good pharmacokinetic properties, fast absorption, broad distribution and no cumulative toxicity (Cheng et al., 2007; Wu et al., 2013; Zeng et al., 2013; Han et al., 2015). In this study, we synthesized a new compound, Statmp-151, by combining ligustrazine and Stattic with the aid of virtual screening and rational drug design.

First, we evaluated the anti-tumour activity of Statmp-151 in vitro by MTT assays and colony formation assays. In both tests, Statmp-151 inhibited the proliferation of 4T1, MDA-MB-231, and MCF-7 breast cancer cells in a dose-dependent manner. Then, we verified the apoptosis-inducing effect of Statmp-151 on tumour cells. Our results showed that Statmp-151 induced mitochondrial membrane potential loss and reduced Bcl-2 expression. The steady state of ROS is correlated with the stability of the membrane potential. In view of this, we found that Statmp-151 significantly changed the ROS levels, suggesting that the effect of Statmp-151 on inducing apoptosis was related to changes in ROS levels and mitochondrial membrane potential. Furthermore, we found that Statmp-151 has an anti-tumour effect by inhibiting the phosphorylation of Stat3. Next, we evaluated the effect of Stamp-151 on the migration of breast cancer cells. Wound-healing migration assays confirmed that Statmp-151 could significantly inhibit cell migration. MMP2 and MMP9 are considered to be transport-related proteins, and protein analysis of 4T1 cells showed significant inhibition of MMP2 and MMP9 protein expressions. Our experiments confirmed that Statmp-151 significantly inhibited tumour growth, and there was no significant change in body weight, organ weight, serum biochemistry or haematoxylin-eosin staining in mice, suggesting that Statmp-151 may have no toxic effects in vivo.

In summary, Statmp-151 is a small molecule compound that was confirmed to inhibit the growth of breast cancer cells in vitro and in vivo by blocking Stat3 activation in this study. Based on
our preliminary investigations on the various pharmacological properties of Statmp-151, it has good anti-tumour activity and is relatively safe. Additionally, Statmp-151 can undergo continued chemical optimization and pharmacological exploration. Therefore, Statmp-151 is worthy of continued development and is a drug candidate for the treatment of breast cancer.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Committee on the Ethics of Animal Experiments of Sichuan University.

REFERENCES

Alehaer, W. B., Alqudah, D. A., Wehabi, S., Abuarquub, D., Zählf, M., Hatmal, M. M. M., et al. (2019). Downregulation of STAT3, β-catenin, and notch-1 by single and combinations of siRNA treatment enhance chemosensitivity of wild type and doxorubicin resistant MCF7 breast cancer cells to doxorubicin. Int J Mol Sci. 20 (15), 3696. doi:10.3390/ijms20153696

Burke, P. J. (2017). Mitochondria, bioenergetics and apoptosis in cancer. Trends Cancer 3 (12), 857–870. doi:10.1016/j.trecan.2017.10.006

Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., et al. (2013). Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur. J. Med. Chem. 62, 498–507. doi:10.1016/j.ejmech.2013.01.023

Cheng, X., Zhang, L. J., Sun, L., and Du, G. (2007). Neutrophilic effects of tetramethylpyrazine on hydrogen peroxide-induced apoptosis in PC12 cells. Cell Biol. Int. 31 (5), 438–443. doi:10.1002/cbl.2006.10.001

Federica, L., Fabio, C., Giovanni, M., and Carmine, S. (2018). STAT3 Interactors as potential therapeutic targets for cancer treatment. Int. J. Mol. Sci. 19 (6), 1787. doi:10.3390/ijms19061787

Furtek, S. L., Backos, D. S., Matheson, C. J., and Reigan, P. (2016). Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. 11 (2), 308–318. doi:10.1021/acschembio.5b00945

Han, J., Song, J., Li, X., Zhu, M., Guo, W., Xing, W., et al. (2015). Ligustrazine suppresses the growth of HRPC cells through the inhibition of cap-dependent translation via both the mTOR and the MEK/ERK pathways. Anticancer Agents Med Chem. 15 (6), 764–772. doi:10.2174/18712061566613050112120

Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., et al. (2019). Breast cancer. Nat. Rev. Dis. Primers. 5 (1), 66. doi:10.1038/s41572-019-0111-2

Heppner, G. H., Miller, F. R., and Shekhar, P. M. (2000). Nontransgenic models of breast cancer. Breast Cancer Res. 2 (5), 331–334. doi:10.1186/bcr77

Ji, P., Xu, X., Ma, S., Fan, J., Zhou, Q., Mao, X., et al. (2015). Novel 2-carboxylbenzo[ b]thiophene 1,1-dioxide derivatives as potent inhibitors of STAT3 signaling pathway. ACS Med. Chem. Lett. 6 (9), 1010–1014. doi:10.1021/acsmchemlett.5b00228

Li, S., Chen, H., Wang, X., Wu, J., Jiang, J., and Wang, Y. (2011). Pharmacokinetic study of a novel stroke therapeutic, 2-[(1,1-dimethylthoxy)oxidoiminomethyl]3,5,6-trimethylpyrazine, by a simple HPLC-UV method in rats. Eur. J. Drug Metab. Pharmacokinet. 36 (2), 95–101. doi:10.1007/s13318-011-0032-2

Li, Y., Gan, C., Zhang, Y., Yu, Y., Fan, C., Deng, Y., et al. (2019). Inhibition of Stat3 signaling pathway by natural product pectolinarigenin attenuates breast cancer metastasis. Front. Pharmacol. 10, 1195. doi:10.3389/fphar.2019.01195

Li, Y., Yang, F., Zheng, W., Hu, M., Wang, J., Ma, S., et al. (2016). Punica granatum (pomegranate) leaves extract induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in non-small cell lung cancer in vitro. Biomed. Pharmacother. 80, 227–235. doi:10.1016/j.biopha.2016.03.023

Liu, Z., Ge, X., Gu, Y., Huang, Y., and Liu, Y. (2019). Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo. Biom Pharma. 121, 109502. doi:10.1016/j.biopha.2019.109502

Lu, Y., and Liu, W. (2020). Selective estrogen receptor degraders (SERDs): a promising strategy for estrogen receptor positive endocrine-resistant breast cancer. J. Med. Chem. 63 (24), 15094–15114. doi:10.1021/acs.jmedchem.0c00913

Pan, J., Shang, J. F., Jiang, G. Q., and Yang, Z. X. (2015). Ligustrazine induces apoptosis of breast cancer cells in vitro and in vivo. J. Cancer Res. Ther. 11 (2), 454–458. doi:10.4103/0973-1482.147378

Reed, J. C. (1997). Cytochrome c: can’t live without it and can’t live without it. Cell. 91 (5), 559–562. doi:10.1016/s0092-8674(00)80442-0

Schust, J., Sperl, B., Hollis, A., Mayer, T. U., and Berg, T. (2006). Stattic: a small molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13 (11), 1235–1242. doi:10.1016/j.chembiol.2006.09.018

Sharma, P. (2018). Update on the treatment of early-stage. Triple-negative breast cancer. Curr. Treat. Options. Oncol. 19 (5), 22. doi:10.1007/s11864-018-0539-8

Shen, J., Zeng, L., Pan, L., Yuan, S., Wu, M., and Kong, X. (2018). Tetramethylpyrazine regulates breast cancer cell viability, migration, and apoptosis by affecting the activity of Akt and caspase-3. Oncol. Lett. 15(4): 4557–4563. doi:10.3892/ol.2018.7851

Waks, A. G., and Winer, E. P. (2019). Breast cancer treatment. JAMA 321 (3), 288–300. doi:10.1001/jama.2018.19323

Wu, W., Yu, X., Luo, X.-P., Yang, S.-H., and Zheng, D. (2013). Tetramethylpyrazine protects against scopolamine-induced memory impairments in rats by reversing the cAMP/PKA/CREB pathway. Behav. Brain Res. 253 (18), 212–216. doi:10.1016/j.bbr.2013.07.052

Xie, Q., Yang, Z., Huang, X., Zhang, Z., and Ma, J. (2019). Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway. J. Hematol. Oncol. 12(1), 60. doi:10.1186/s13045-019-0744-3

Yang, F., Hu, M., Lei, Q., Xia, Y., Zhu, Y., Song, X., et al. (2015). Nifuroxazeid induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis. 6 (3), e1701. doi:10.1038/cddis.2015.63

Zeng, L., Li, W., and Chen, C. S. (2020). Breast cancer animal models and applications. Zool. Res. 41 (5), 477–494. doi:10.24272/j.issn.2095-8137.2020.095

Zeng, M., Pan, L., Qi, S., Cao, Y., Zhu, H., Guo, L., et al. (2013). Systematic review of recent advances in pharmacokinetics of four classical Chinese medicines used for the treatment of cerebrovascular disease. Fitoterapia 88, 50–75. doi:10.1016/j.fitote.2013.04.006

AUTHOR CONTRIBUTIONS

CF, YW, HH, WL, JM, DY, and TX: Experiment and Data analysis. LH and YR: Data analysis. YZ, QW, and YX: Writing. YL, RT, and JG: Conception, design, data analysis and writing. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the International Cooperation Project of Science and Technology Department of Sichuan Province (2019YFH119, 2021YFH173), Chengdu Science and Technology Bureau International Cooperation Project (No. 2019-GH02-00036-HZ).
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., and Turkson, J. (2010). A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. *Biochem. Pharmacol.* 79 (10), 1398–1409. doi:10.1016/j.bcp.2010.01.001

Zhao, Y., Liu, Y., and Chen, K. (2016). Mechanisms and clinical application of tetramethylpyrazine (an interesting natural compound isolated from ligusticum wallichii): current status and perspective. *Oxidative Med. Cell Longevity.* 2016, 1. doi:10.1155/2016/2124638

Zhu, Y., Wei, W., Ye, T., Liu, Z., Liu, L., Luo, Y., et al. (2016). Small molecule TH-39 potentially targets Hec1/Nek2 interaction and exhibits antitumor efficacy in K562 cells via G0/G1 cell cycle arrest and apoptosis induction. *Cell Physiol Biochem* 40 (1-2), 297–308. doi:10.1159/000452546

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Fan, Wang, Huang, Li, Ma, Yao, Tang, Xue, Ha, Ren, Zhang, Wang, Xie, Luo, Tan and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.